The new anti-epileptic drugs.
Murphy
R
R
D000612:4-Aminobutyrate Transaminase / Q000037:antagonists & inhibitors; D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use; D000588:Amines; D000927:Anticonvulsants / Q000008:administration & dosage / Q000145:classification / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids; D004338:Drug Combinations; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D004827:Epilepsy / Q000145:classification / Q000188:drug therapy / Q000601:surgery; D000077206:Gabapentin; D006801:Humans; D000077213:Lamotrigine; D014227:Triazines / Q000008:administration & dosage / Q000627:therapeutic use; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D004338:Drug Combinations; D004791:Enzyme Inhibitors; D014227:Triazines; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D000612:4-Aminobutyrate Transaminase; D020888:Vigabatrin; D000077213:Lamotrigine